Paige Bischoff – VJRegenMed

The importance of specialty medical centers in delivering ATMPs

admin_vjr_user — Mon, 05 Jul 2021 13:47:07 +0000

Paige Bischoff, Senior VP of Global Public Affairs, Alliance for Regenerative Medicine (ARM), Washington, D.C., discusses the important role of large specialty medical centers in the delivery of advanced therapy medicinal products (ATMPs) to patients with rare diseases. The need for patients to travel across borders between countries to these specialist centers highlights the importance of regulatory harmonization in improving patient access to therapies. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

The European cell & gene therapy landscape

admin_vjr_user — Sat, 10 Apr 2021 10:58:01 +0000

Paige Bischoff, Senior VP of Global Public Affairs, Alliance for Regenerative Medicine (ARM), Washington, D.C., provides an overview of the cell and gene therapy sector in Europe. In 2021, there are currently five approved gene therapies and six cell therapies on market in Europe but it is predicted that by 2025, the European Medicines Agency (EMA) will approve 10-20 new cell and gene therapies each year. It is therefore important that current challenges surrounding policy, regulation and reimbursement are addressed in the near future. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

Supporting the future of ATMPs in the EU

admin_vjr_user — Sat, 10 Apr 2021 10:57:59 +0000

Paige Bischoff, Senior VP of Global Public Affairs, Alliance for Regenerative Medicine (ARM), Washington, D.C., discusses the future of the policy and regulatory landscape for advanced therapy medicinal products (ATMPs) in the European Union (EU) and how ARM aims to support the sector’s growth in the coming years. She describes the importance of implementing innovative payment models for ATMPs in Europe and how the use of real-world evidence should be incorporated into health technology assessment (HTA) frameworks going forward. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

Putting the patient first in regenerative medicine

admin_vjr_user — Fri, 09 Oct 2020 16:47:09 +0000

Regenerative medicine is transforming the patient experience with innovative therapies. Paige Bischoff, Senior VP, Alliance for Regenerative Medicine (ARM), Washington, DC, discusses the importance of the patient’s voice, and the impact these therapies are having on people. This interview took place during the 2020 Meeting on the Mesa congress.

Spotlight on key sessions at the 2020 ARM Meeting on the Mesa

admin_vjr_user — Fri, 09 Oct 2020 16:47:09 +0000

The Cell & Gene Meeting on the Mesa provides key players in both industry and academia a forum to share vital updates in the field, and ultimately further therapeutic advances and cutting-edge research. Paige Bischoff, Senior VP, Alliance for Regenerative Medicine (ARM), Washington, DC talks on the key sessions that will be presented at the meeting, including the impact of COVID-19, the promise of regenerative medicine, and perspectives from the pioneers in the sector. This interview took place during the 2020 Meeting on the Mesa congress.

A new model for cell and gene therapies

admin_vjr_user — Fri, 09 Oct 2020 16:47:09 +0000

With the continued growth of the regenerative medicine sector, the importance of advocacy also continues to grow. Paige Bischoff, Senior VP, Alliance for Regenerative Medicine (ARM), Washington, DC, talks on the innovative payment models that need to be sought after in light of the high upfront costs of extremely durable regenerative medicine therapies. This interview took place during the 2020 Meeting on the Mesa congress.

Paige Bischoff, Senior VP, Public Affairs, Alliance for Regenerative Medicine

admin_vjr_user — Fri, 09 Oct 2020 16:47:09 +0000

Paige Bischoff, Senior VP, Alliance for Regenerative Medicine (ARM), Washington, DC, talks on her role at ARM and the effective communication strategy recently implemented at the organization. This interview took place during the 2020 Meeting on the Mesa congress.